ClinicalTrials.gg
RecruitingNCT07931482ReMiUpdated Nov 12, 2026

Revitalis - Midface (Cheek Area)

An interventional study of Croma revitalis in Skin Smoothness, sponsored by Croma-Pharma GmbH. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Croma-Pharma GmbH · Not applicable, Interventional, and Treatment

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To evaluate the effects and safety of croma revitalis in improving midface (cheek area) skin smoothness

02

Conditions studied

  • Skin Smoothness
03

In context

Lead sponsor

Croma-Pharma GmbH is the lead sponsor of 26 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18- 75 years (inclusive) at screening.
  2. Willing and able to provide written prior to any study related procedure.
  3. Willing and able to comply with all study-related requirements, including visit schedule, treatment procedures, and follow-up assessments.
  4. Moderate to severe deficit in midface (cheek area) skin smoothness, as assessed by the live evaluator on the Canfield Skin Quality Scale - Skin Smoothness (CSQS-SS).
  5. Healthy skin in the treatment area.
  6. Willingness to refrain from other aesthetic procedures during thestudy.
  7. For females of : negative urine pregnancy test and agreement to use a highly effective method of throughout the entire study.
  8. For male participants with female partners of child-bearing potential: agreement to use contraception throughout the entire study such as surgical sterilization or a physical barrier such as a condom.
  9. FACE-Q™ Satisfaction with Skin score 39 or less at screening (equivalent of Rash-transformed score of 69).

Exclusion criteria

Exclusion Criteria:

  1. Females, who are pregnant and/ or breastfeeding or planning to become pregnant during the clinical investigation.
  2. Known or allergy to hyaluronic acid preparations, gram-positive bacterial proteins, or any component of the device.
  3. History or presence of severe allergic reactions, anaphylaxis, or multiple severe allergies.
  4. History or current diagnosis of or connective tissue disease, or current use of or immunomodulating therapy.
  5. Presence of active infection, inflammation, or pre-malignant/ malignant lesions in the treatment area.
  6. Active herpes simplex infection in the treatment area.
  7. Known tendency to develop keloids, hypertrophic scars, or pigment disorders.
  8. Any prior treatment or planned treatment with permanent or semipermanent dermal fillers, in the treatment area or adjacent areas that may interfere with the study assessments
  9. Use of anticoagulants, antiplatelet agents, NSAIDs, or thrombolytics
  10. Known or suspected bleeding disorders associated with increased risk of injection-related complications.
  11. Recent or planned treatment with temporary dermal fillers, botulinum toxin, mesotherapy, laser treatments, chemical peels, dermabrasion, thread-based lifting, or energy-based devices (including, but not limited to, devices for muscle mass improvement or collagen stimulation) in the treatment area or adjacent areas that may interfere with the study assessments , within 12 months prior to screening.
  12. Presence of acute skin conditions in the treatment area, including acne, cysts, rashes, hives, or other inflammatory skin disorders.
  13. Any other condition that would compromise the participant's safety or interfere with study participation or data interpretation, including but not limited to marked hyperpigmentation, acne scarring, severe textural irregularities, facial tattoos, excessive facial hair (e.g. patients unwilling to shave the beard) or other conditions judged by the investigator.
  14. Any condition or situation that, in the opinion of the investigator, may interfere with study participation or interpretation of results, including mental disorders.
  15. Previous treatment administration in this clinical investigation.
  16. Current participation in another clinical trial, or treatment with any investigational drug/ medical device within 30 days prior to screening or within five half-lives of an investigational drug, whichever is longer and during the entire investigation.
  17. Individuals whose willingness to volunteer in this clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate (e.g., persons with a legal custodian appointed due to mental disability, prisoners, soldiers and other members of the armed forces, civil servants).
  18. Close affiliation with the investigator or employment relationship with the sponsor or sponsor-affiliated companies that may create bias or undue influence.
  19. Covid vaccination received within the past 3 weeks before screening or planning to receive in the 2 weeks following the treatment.
  20. Patients with facial dysmorphic features that may interfere with study assessments.
  21. Patients under strict diet or intending to lose weight.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    croma revitalis

    Croma revitalis is a (CE)-marked, non-active, single-use hyaluronic acid-based medical device, intended for intradermal administration in the midface (cheek area).

    Device: Croma revitalis

Interventions

  • DeviceCroma revitalis

    Croma revitalis is a hyaluronic acid-based injectable gel for soft tissue implantation and intradermal aesthetic use. 1 mL per cheek side per treatment session, distributed across 4 intradermal injection points (0.25 mL each) using a standardized injection technique with a sterile needle at baseline Week 0, Week 3, and Week 6. After week 6 a follow up period until week 30 is performed at week 9, 12, 16, 20, 24 and 30.

06

What researchers measure

Primary outcomes

  1. Skin Smoothness: Responder status assessed by independent evaluator at site

    Responder status as assessed by a live independent evaluator at site using the validated Canfield Skin Quality Scale - Skin Smoothness (CSQS-SS)

    Time frame: week 12

Secondary outcomes

  1. Skin Smoothness: Responder status assessed by independent evaluator at site - other timepoints

    To evaluate improvement in midface (cheek area) skin smoothness using the validated CSQS-SS at additional study timepoints, as assessed by a live independent evaluator at site

    Time frame: week 9, week 16, week 20, week 24, week 30

  2. Skin Smoothness: Responder status assessed by blinded panel

    To evaluate improvement in midface (cheek area) skin smoothness using the validated CSQS-SS at additional study timepoints, as assessed by a blinded panel of three independent evaluators via photographic review.

    Time frame: week 9, week 12, week 16, week 20, week 24, week 30

  3. Skin Smoothness: Change from Baseline assessed by independent evaluator at site

    Change from baseline in CSQS-SS scores based on assessment of both sides by a live independent evaluator at site

    Time frame: Week 9, 12, 16, 20, 24 and 30

  4. Skin Smoothness: Change from baseline assessed by blinded panel

    Change from baseline in CSQS-SS scores based on the blinded panel of three independent evaluators via photographic review assessment

    Time frame: Week 9, 12, 16, 20, 24 and 30

  5. Cheek Lines: Responder Status assessed by independent evaluator at site

    Responder status at follow-up time points based on CSQS-CL assessment by a live independent evaluator at site

    Time frame: Week 9, 12, 16, 20, 24, and 30

  6. Cheek Lines: Change from Baseline assessed by independent evaluator at site

    Change from baseline in CSQS-CL scores based on assessment of both sides by a live independent evaluator at site.

    Time frame: Week 9, 12, 16, 20, 24 and 30

  7. Cheek Lines: Responder status assessed by blinded panel

    Responder status at follow-up time points based on blinded panel of three independent evaluators via photographic review assessment using CSQS-CL.

    Time frame: Week 9, 12, 16, 20, 24, and 30

  8. Cheek Lines: Change from Baseline assessed by blinded panel

    Change from baseline in CSQS-CL scores, based on the blinded panel of three independent evaluators via photographic review assessment

    Time frame: Week 9, 12, 16, 20, 24 and 30

  9. FACE-Q™ Satisfaction with Skin

    Participant-reported outcomes using FACE-Q™ Satisfaction with Skin

    Time frame: Week 9, 12, 16, 20, 24 and 30

  10. FACE-Q™ Satisfaction with Outcome

    Participant-reported outcomes using FACE-Q™ Satisfaction with Outcome

    Time frame: Week 9, 12, 16, 20, 24 and 30

  11. FACE-Q™Lines Appraisal

    Participant-reported outcomes using FACE-Q™ Lines Appraisal

    Time frame: Week 9, 12, 16, 20, 24 and 30

  12. GAIS assessed by the participants

    Global Aesthetic Improvement Scale (GAIS) assessed by the participants

    Time frame: Week 9, 12, 16, 20, 24, and 30

  13. GAIS assessed by an independent evaluator at site

    Global Aesthetic Improvement Scale (GAIS) assessed by and independent evaluator at site

    Time frame: Week 9, 12, 16, 20, 24, and 30

  14. Skin hydration: change from baseline

    Change from baseline in midface (cheek area) skin hydration as measured by corneometer

    Time frame: Week 9, 12, 16, 20, 24, and 30

  15. Skin elasticity: change from baseline

    Change from baseline in midface (cheek area) skin elasticity as measured by cutometer

    Time frame: Week 9, 12, 16, 20, 24, and 30

  16. Skin firmness(tone): change from baseline

    Change from baseline in midface (cheek area) skin firmness(tone) as measured by cutometer

    Time frame: Week 9, 12, 16, 20, 24, and 30

Other outcomes

  1. Safety Events occurence

    Occurrence, severity, and relationship to treatment of AEs, SAEs, and ADEs throughout the study

    Time frame: From first treatment, up to 30 weeks after first treatment ( until study completion or withdrawal)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2026 (actual). Primary completion is estimated for Oct 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 12, 2026
StartActual
Nov 4, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07931482
Lead sponsor
Croma-Pharma GmbH
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Nov 4, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Operations Head
Contact
clinical.studies@croma.at
+43676846868370

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion